Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for details on EVO ICL adoption, new FDA indications, or the cost of expanding Staar Surgical’s Swiss manufacturing line? Those answers live inside the company’s SEC documents—but combing through a 300-page annual report can be daunting. This page gathers every Staar Surgical SEC filing in one place and pairs it with AI-powered explanations so you can focus on the numbers, not the jargon.
Whether you need a Staar Surgical quarterly earnings report 10-Q filing before tomorrow’s call or want to monitor Staar Surgical insider trading Form 4 transactions in real time, our platform surfaces the right document instantly and highlights the sections that matter. Expect:
- Staar Surgical annual report 10-K simplified with key metrics on lens unit growth and geographic revenue mix.
- Form 4 alerts that flag Staar Surgical executive stock transactions Form 4 minutes after they hit EDGAR.
- 8-K material events explained—quality-system audits, regulatory approvals, or distributor agreements—in clear language.
Each filing also comes with concise AI summaries, ratio tables, and plain-English answers to common questions such as “How is R&D capitalised?” or “What does the proxy statement say about executive compensation?” By understanding Staar Surgical SEC documents with AI, you can quickly spot shifts in gross margin, track insider sentiment, and compare quarter-over-quarter lens shipments—without wading through dense legal text. From Staar Surgical proxy statement executive compensation details to Staar Surgical earnings report filing analysis, every document is updated in real time and fully searchable. Complex ophthalmic disclosures, now clear and actionable.
Staar Surgical has reported a significant insider transaction involving their newly appointed Chief Financial Officer, Deborah J. Andrews. On June 25, 2025, Andrews received a grant of 41,867 Restricted Stock Units (RSUs) as part of her appointment compensation package.
Key details of the RSU grant:
- Each RSU represents the right to receive one share of common stock upon vesting
- The RSUs will vest in three equal annual installments on June 25 of 2026, 2027, and 2028
- The conversion price is $0, typical for RSU grants
- The shares are held directly by Andrews
This Form 4 filing indicates a standard executive compensation arrangement, designed to align the new CFO's interests with long-term shareholder value through a three-year vesting schedule. The transaction was reported within the required two-business-day window for insider transaction disclosure.
STAAR Surgical Co. (STAA) Form 4 filing: Director Lilian Y. Zhou, Chair of the Capital Stewardship Committee, was granted 4,363 non-qualified stock options on 25 June 2025 under the company’s annual non-employee director equity program. The options carry an exercise price of $16.72 and expire 24 June 2035. Vesting occurs quarterly in four equal tranches—25 September 2025, 25 December 2025, 25 March 2026, and 25 June 2026—resulting in full vesting within one year. Following the grant, Zhou beneficially owns 4,363 derivative securities directly. No sales, exercises, or additional equity transactions were reported. The filing represents routine director compensation and does not indicate changes in ownership of outstanding common shares.
STAAR Surgical (NASDAQ:STAA) announced the appointment of Deborah Andrews as Chief Financial Officer, effective June 25, 2025. Andrews, who has served as Interim CFO since March 2025, previously retired from STAAR in 2020 after over 20 years with the company, including serving as CFO from 2017-2020.
Under her compensation package, Andrews will receive a $495,000 annual base salary with a 55% target bonus and equity awards valued at $1.4 million. The company also announced the formation of a new Capital Stewardship Committee, chaired by board member Lilian Y. Zhou, to oversee financial strategies and capital allocation.
Form 4 filing overview – STAAR Surgical Co. (STAA)
On 18 June 2025, non-employee director Louis E. Silverman received an equity award under STAAR Surgical’s annual non-employee director compensation program. The transaction was reported on 20 June 2025.
- Security type: Restricted Stock Units (RSUs)
- Quantity granted: 10,683 RSUs, each representing the right to one share of common stock upon vesting
- Transaction code: “A” (grant, no open-market price; stated value $0)
- Vesting schedule: 100% on the earlier of 18 June 2026 or the company’s 2026 Annual Meeting of Shareholders
- Post-grant derivative holdings: 10,683 RSUs held directly
No open-market purchases or sales of common shares were reported, and the filing contains no indication of indirect ownership arrangements. The grant reflects routine board compensation and does not, by itself, alter STAAR Surgical’s capital structure or provide insight into operating performance, but it does align the director’s incentives with shareholder value over the coming year.
STAAR Surgical Co. (STAA) – Form 4 insider filing dated June 20, 2025
Director Wei Jiang reported the receipt of 10,683 Restricted Stock Units (RSUs) on June 18, 2025 under the company’s annual non-employee director equity compensation program for the 2025-2026 term. Each RSU converts into one share of common stock upon vesting. The award vests in full on the earlier of June 18, 2026, or the 2026 Annual Meeting of Shareholders. The filing lists the RSUs at a conversion price of $0, and no shares were sold or disposed of. Following the grant, Ms. Jiang’s directly held derivative equity position totals 10,683 RSUs; no indirect ownership is disclosed.
Because the transaction is an automatic annual equity award and does not involve open-market purchases or sales, there is no immediate cash outflow or inflow for either the insider or the company. The filing primarily signals continued board-level alignment with shareholder interests but is not expected to be financially material to STAAR Surgical’s capitalization or share count.
Key take-away: STAAR Surgical Co. (STAA) has filed a Form 4 disclosing a routine equity compensation grant to non-employee director Lilian Yansheng Zhou.
On 18 June 2025 the director received 19,415 non-qualified stock options with an exercise price of $16.85 per share (Transaction Code "A"). The options vest in full on the earlier of 18 June 2026 or the company’s 2026 Annual Meeting of Shareholders and carry an expiration date of 17 June 2035. No open-market purchases or sales of common stock were reported, and there was no change in the director’s non-derivative share holdings.
The filing is made by a single reporting person and reflects the company’s standard annual equity program for non-employee directors. Given the modest size relative to STAAR’s total share count and the absence of trading activity, the disclosure is viewed as routine with limited market impact.
Form 4 overview: On 06/18/2025 STAAR Surgical Co. (STAA) granted Director Arthur C. Butcher equity under its 2025-2026 non-employee director compensation program.
- Restricted Stock Units (RSUs): 5,341 units acquired at $0. Each RSU converts into one common share when vested. Vesting occurs in full on the earlier of 18 Jun 2026 or the company’s 2026 annual meeting.
- Stock options: 9,708 options with a $16.85 exercise price. Options vest 18 Jun 2026 and expire 17 Jun 2035.
No dispositions were reported; all transactions are coded “A” (acquisition). Ownership is listed as direct, indicating the director holds the awards personally. The filing is routine compensation disclosure and does not contain earnings or operational data.
STAAR Surgical Co. (STAA) – Form 4 insider filing
On 18 June 2025, non-employee director Dr. Elizabeth Yeu received her annual board equity package:
- Restricted Stock Units (RSUs): 5,341 – each RSU converts to one common share upon vesting.
- Stock Options: 9,708 – exercise price $16.85, expire 17 June 2035.
On 18 June 2025, STAAR Surgical Company (STAA) convened its 2025 Annual Meeting of Shareholders with a strong quorum of 44,746,693 shares (≈90% of the 49.5 million outstanding).
Director elections (Proposal 1): All six nominees were re-elected for terms expiring at the 2026 meeting. Shareholder support ranged from 96%–99% of votes cast, with Arthur C. Butcher receiving 41.1 million “For” votes and Lilian Y. Zhou receiving 41.9 million.
Auditor ratification (Proposal 2): BDO USA, P.C. was confirmed as independent auditor for fiscal 2025 with 44,463,071 “For” votes (≈99%), only 273,085 “Against,” and 10,537 abstentions.
Say-on-Pay advisory vote (Proposal 3): Compensation of named executive officers was approved on a non-binding basis, receiving 41,130,690 “For” votes (≈97.5%), 1,049,897 “Against,” 24,667 abstentions, and 2,541,439 broker non-votes.
No other matters were brought before the meeting, and no substantive changes to corporate strategy or financial guidance were disclosed.
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
What is the primary focus of Staar Surgical Co?
What types of implantable lenses does the company offer?
How does Staar Surgical differentiate itself in the ophthalmic surgery market?
What are the key benefits of using implantable lenses from Staar Surgical?
How does the company ensure the quality and safety of its products?
In what ways are the company’s products integrated into surgical procedures?
How does Staar Surgical contribute to advancements in ophthalmic surgery?
